M&A Deal Summary

neuraxpharm Acquires Brain Therapeutics

On March 8, 2022, neuraxpharm acquired medical products company Brain Therapeutics

Acquisition Highlights
  • This is neuraxpharm’s 1st transaction in the Medical Products sector.
  • This is neuraxpharm’s 1st transaction in Greece.

M&A Deal Summary
Date 2022-03-08
Target Brain Therapeutics
Sector Medical Products
Buyer(s) neuraxpharm
Deal Type Add-on Acquisition

Target

Brain Therapeutics

Athens, Greece
Brain Therapeutics specializes in the in-licensing and commercialization of pharmaceutical products in the CNS therapy area to address the unmet medical needs of patients with mental, neurological, neurodevelopmental, or neurodegenerative disorders, as well as anesthesia and pain. Brain Therapeutics is headquartered in Athens, Greece.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

neuraxpharm

Langenfeld, Germany
Category Company
Founded 1985
Sector Life Science
Revenue 460M EUR (2019)
DESCRIPTION

neuraxpharm is a provider of generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). neuraxpharm was formed in 1985 and is based in Langenfeld, Germany.

DEAL STATS #
Overall 4 of 4
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 3 of 3
Country (Greece) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-14 Aribamed

Dublin, Ireland

Aribamed provides and maintains important niche medicines on the Irish market for use by specialists, who find them for some patients. Aribamed partners with pharmaceutical manufacturers to commercialize niche pharmaceuticals with differential benefits for individual patients on the Irish market to support medical specialists in hospitals and specialist centers Aribamed was founded in 2007 and is based in Dublin, Ireland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-04-27 Inke

Castellbisbal, Spain

Inke is a developer and manufacturer of the quality active pharmaceutical ingredients (APIs) with complex synthesis processes, mainly for use in respiratory therapies. Inke is a key supplier to major generic and branded companies worldwide, having twelve respiratory APIs for inhalation in its portfolio and distributing its products to more than 40 countries including Europe, the US, Japan, Korea, China and Turkey. Inke was founded in 1980 and is based in Castellbisbal, Spain.

Sell -
Mergr

Product

Company

Legal